RAY B Stock Overview
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RAY B from our risk checks.
My Notes
Capture your thoughts, links and company narrative
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 205.00 |
| 52 Week High | SEK 218.00 |
| 52 Week Low | SEK 84.10 |
| Beta | 1.34 |
| 1 Month Change | 5.67% |
| 3 Month Change | 23.79% |
| 1 Year Change | 126.52% |
| 3 Year Change | 262.19% |
| 5 Year Change | 84.19% |
| Change since IPO | 36,076.90% |
Recent News & Updates
Recent updates
RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares Climb 28% But Its Business Is Yet to Catch Up
Nov 09
RaySearch Laboratories AB (publ) (STO:RAY B) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
May 21The Returns At RaySearch Laboratories (STO:RAY B) Aren't Growing
May 11RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends
Oct 04Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?
Jul 10Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?
Nov 17One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be
Mar 15Is RaySearch Laboratories (STO:RAY B) A Risky Investment?
Feb 22Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?
Nov 04Shareholder Returns
| RAY B | SE Healthcare Services | SE Market | |
|---|---|---|---|
| 7D | 2.0% | -3.3% | -2.2% |
| 1Y | 126.5% | 59.7% | 6.1% |
Return vs Industry: RAY B exceeded the Swedish Healthcare Services industry which returned 59.7% over the past year.
Return vs Market: RAY B exceeded the Swedish Market which returned 6.1% over the past year.
Price Volatility
| RAY B volatility | |
|---|---|
| RAY B Average Weekly Movement | 6.7% |
| Healthcare Services Industry Average Movement | 5.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: RAY B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: RAY B's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 414 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
RaySearch Laboratories AB (publ) Fundamentals Summary
| RAY B fundamental statistics | |
|---|---|
| Market cap | SEK 6.93b |
| Earnings (TTM) | SEK 175.06m |
| Revenue (TTM) | SEK 1.17b |
40.1x
P/E Ratio6.0x
P/S RatioIs RAY B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAY B income statement (TTM) | |
|---|---|
| Revenue | SEK 1.17b |
| Cost of Revenue | SEK 104.50m |
| Gross Profit | SEK 1.06b |
| Other Expenses | SEK 889.45m |
| Earnings | SEK 175.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | 5.11 |
| Gross Margin | 91.06% |
| Net Profit Margin | 14.97% |
| Debt/Equity Ratio | 0% |
How did RAY B perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield14%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 18:36 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RaySearch Laboratories AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Hans Mähler | DNB Markets |
| Hans Mähler | Handelsbanken Capital Markets |